Pancreatic Cancer Research

ResearcherUniversity of Southern DenmarkActive in the last 2 years

Sönke Detlefsen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9466-2333; OpenAlex author ID A5091308274. Sources: ClinicalTrials.gov.

Their work

Papers
32 (first author 2, last author 14)
Trials
1
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 4 papers, 1 trial · 2021: 6 papers · 2022: 1 paper · 2023: 4 papers · 2024: 6 papers · 2025: 2 papers · 2026: 2 papers

Papers 32

  1. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for pancreatic cancer peritoneal metastases: A retrospective multicentric study from the ISSPP PIPAC D… Co-author DOI 10.1016/j.ejso.2026.112078↗
  2. Circulating tumour DNA as a prognostic tool for surgically treated pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.humpath.2025.106024↗
  3. Utility of peritoneal fluid for multiplexed mRNA profiling of peritoneal metastasis from pancreatic cancer. Last author DOI 10.1016/j.prp.2025.156250↗
  4. Preoperative EUS-guided biopsy does not affect survival in patients with pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1097/eus.0000000000000156↗
  5. Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients. Co-author DOI 10.1016/j.isci.2024.111026↗
  6. Exploring the prognostic value of circular RNAs in pancreatic ductal adenocarcinoma using genome-wide expression profiling. Last author DOI 10.1016/j.pan.2024.04.004↗
  7. Prognostic value of margin clearance in total and distal pancreatectomy specimens with pancreatic ductal adenocarcinoma in a Danish population-based nationwide… Last author DOI 10.1016/j.prp.2023.155077↗
  8. Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study. Co-author DOI 10.1016/j.radonc.2024.110347↗
  9. Identification of tumour regression in neoadjuvantly treated pancreatic cancer is based on divergent and nonspecific criteria. Co-author DOI 10.1111/his.15190↗
  10. RNA expression profiling of peritoneal metastasis from pancreatic cancer treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Co-author DOI 10.1515/pp-2024-0001↗
  11. Prognostic significance of margin clearance in pancreaticoduodenectomy specimens with pancreatic ductal adenocarcinoma in a Danish population-based nationwide … Last author DOI 10.1016/j.hpb.2023.03.016↗
  12. High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocar… Co-author DOI 10.1016/j.humpath.2023.11.002↗
  13. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Co-author DOI 10.1186/s12885-023-11035-6↗
  14. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Co-author DOI 10.21203/rs.3.rs-2955930/v1↗
  15. Whole genome sequencing identifies rare genetic variants in familial pancreatic cancer patients. Co-author DOI 10.1111/ahg.12464↗
  16. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens. Last author DOI 10.1016/j.pan.2021.01.025↗
  17. Synchronous detection of pancreatic adenocarcinoma and paraganglioma in a Whipple resection specimen. Last author DOI 10.1016/j.prp.2021.153590↗
  18. Cohort profile and heritability assessment of familial pancreatic cancer: a nation-wide study. Co-author DOI 10.1080/00365521.2021.1937697↗
  19. Whole genome sequencing identifies rare germline variants enriched in cancer related genes in first degree relatives of familial pancreatic cancer patients. Co-author DOI 10.1111/cge.14038↗
  20. Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC. Last author DOI 10.1136/jclinpath-2020-206607↗
  21. Heritability of familial pancreatic cancer in a Danish national family cohort Co-author DOI 10.21203/rs.3.rs-141845/v1↗
  22. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. Co-author DOI 10.1016/j.ejca.2020.01.015↗
  23. Utility of pVHL, maspin, IMP3, S100P and Ki67 in the distinction of autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.prp.2020.152925↗
  24. Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.prp.2020.152985↗
  25. Spatial and phenotypic characterization of pancreatic cancer-associated fibroblasts after neoadjuvant treatment. Last author DOI 10.14670/hh-18-201↗
  26. The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. Co-author DOI 10.1080/0284186x.2019.1581374↗
  27. Value of anti-plasminogen binding peptide, anti-carbonic anhydrase II, immunoglobulin G4, and other serological markers for the differentiation of autoimmune p… Co-author DOI 10.1097/md.0000000000011641↗
  28. Typing of pancreatic cancer-associated fibroblasts identifies different subpopulations. Last author DOI 10.3748/wjg.v24.i41.4663↗
  29. Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). First author DOI 10.1007/s10585-017-9849-7↗
  30. Danish Pancreatic Cancer Database. First author DOI 10.2147/clep.s99471↗
  31. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. Last author DOI 10.3748/wjg.v22.i9.2678↗
  32. [The impact of desmoplasia and pancreatic stellate cells on pancreatic cancer]. Last author PMID 26320589↗

Trials 1

  1. Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer Study director NCT05400681↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Bau Mortensen · 26 shared papers, 2015–2026 · strength 4.28
  2. Per Pfeiffer · 16 shared papers, 2017–2026 · strength 2.72
  3. Claus Wilki Fristrup · 14 shared papers, 2016–2026 · strength 2.51
  4. Trine Aaquist · 4 shared papers, 2021–2026 · strength 0.81
  5. Morten Bækbo Ladekarl · 6 shared papers, 2016–2024 · strength 0.77
  6. Michael Friberg Bruun Nielsen · 6 shared papers, 2015–2020 · strength 0.73
  7. Ove B. Schaffalitzky de Muckadell · 5 shared papers, 2018–2022 · strength 0.71
  8. Martin Graversen · 4 shared papers, 2017–2025 · strength 0.70
  9. Frank Viborg Mortensen · 4 shared papers, 2019–2026 · strength 0.68
  10. Britta Weber · 4 shared papers, 2020–2024 · strength 0.61
  11. Maiken Thyregod Jøergensen · 4 shared papers, 2021–2022 · strength 0.61
  12. Ming Tan · 4 shared papers, 2021–2022 · strength 0.61
  13. Karin de Stricker · 3 shared papers, 2021–2026 · strength 0.57
  14. Lukas Gammelgaard Rasmussen · 3 shared papers, 2021–2024 · strength 0.53
  15. Carsten Palnæs Hansen · 4 shared papers, 2016–2025 · strength 0.51
  16. Louise S. Rasmussen · 4 shared papers, 2019–2023 · strength 0.49
  17. Mogens Tornby Stender · 2 shared papers, 2024–2025 · strength 0.45
  18. Caroline Sophie Verbeke · 2 shared papers, 2021–2024 · strength 0.42
  19. Siri Vreim Ørbeck · 2 shared papers, 2023–2024 · strength 0.39
  20. Susy Shim · 2 shared papers, 2023–2024 · strength 0.36
  21. Gabor Istvan Liposits · 2 shared papers, 2023 · strength 0.32
  22. Stine Brændegaard Winther · 2 shared papers, 2023 · strength 0.32
  23. Julia Sidenius Johansen · 2 shared papers, 2023 · strength 0.32
  24. Inna Markovna Chen · 2 shared papers, 2023 · strength 0.32
  25. Petra Sántha · 1 shared paper, 2024 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.